Clinical review report Levodopa/Carbidopa (Duodopa) (Abbvie Corporation)
The current Common Drug Review (CDR) review was undertaken in response to a request from the drug plans that participate in the CDR review process that the use of levodopa/carbidopa intestinal gel (LCIG) in Parkinson disease (PD) be re-reviewed in light of the availability of new evidence. Therefore...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820282706719 |
